- lead - Jubilant Ingrevia is a chemical company built on a single, recurring idea: take a cheap, bio-based raw material, master one complex chemistry, and then climb the value chain from bulk industrial inputs into high-margin specialty ingredients for pharmaceuticals, agrochemicals, and human nutrition. It was formed as a result of the demerger of the Life Science Ingredients business from Jubilant Life Sciences, but its roots go back over 45 years to making acetic acid and its derivatives. That same playbook - use the cash and know-how from a volume-driven chemical platform to fund the next, more sophisticated business - now runs across three distinct engines, with a fourth being built on top of them.
Business segments
Three engines at different stages - a volume-driven chemical-intermediates cash cow, a global specialty-chemicals leader, and a nutrition platform climbing from animal feed into human health - each built with the cash flows and chemistry of the one before.
1. Specialty Chemicals: the high-value engine built on pyridine mastery
The company is the world’s largest and lowest-cost producer of bio-based pyridine outside China, and it is converting that dominance into a fast-scaling custom-manufacturing business for pharma, agrochemical, and semiconductor innovators.
- World’s biggest pyridine player in terms of sales - it holds the number-one global position in 36 pyridine derivatives with more than 50% market share, and its roughly 50,000-tonne capacity runs at over 90% utilisation at a cost that beats Chinese rivals.
- Diketene is the second growth leg - a new plant making esters, amides and specialty intermediates from diketene chemistry reached about 70% utilisation within two years of start-up, and the company aims to be among the top three global players in this space.
- Custom manufacturing is the future - the CDMO (custom development and manufacturing) arm already runs 15 pharma programmes and has locked in a five-year, USD 300 million-plus contract with a global agrochemical innovator, with a dedicated facility due to start contributing revenue by late FY2026.
- Even semiconductors are on the map - it is developing 8-10 high-purity molecules for chip-industry customers, with sample supplies underway to multiple customers and a dedicated clean-room R&D lab built to support the push.
- A competitor’s exit became its gain - when a close rival shut its US pyridine operations, the company captured the majority of the displaced volumes within weeks, showing how its scale and readiness turn industry shocks into opportunity.
2. Chemical Intermediates: the cash-generating backbone
This is the volume engine that supplies essential building-block chemicals to pharma and agrochemical makers while feeding raw materials into the company’s own higher-value businesses - and it runs on negative working capital.
- India’s acetic anhydride leader - it is the largest supplier in India with over 70% domestic market share and among the top two merchant suppliers globally, with total capacity now at 210,000 metric tonnes after a new 60,000-tonne plant was commissioned in FY2024.
- Bio-based from the start - it is the world’s largest producer of bio-acetaldehyde, made using proprietary technology that emits 173% less CO₂ per tonne than the petrochemical route, and that acetaldehyde is the precursor for its entire pyridine chain.
- Green solvents with a carbon story - its bio-ethanol-based ethyl acetate carries a carbon footprint of 2.29 tonnes of CO₂ per tonne, less than half the 5.66 tonnes of the petrochemical equivalent, which matters to packaging and coatings customers under pressure to decarbonise.
- Just-in-time, globally - it keeps storage hubs in Europe and South Korea so it can supply acetic anhydride without interruption, which is critical because the molecule goes into everyday drugs like paracetamol and ibuprofen.
- Cash that funds the rest - the segment operates with negative working capital, meaning it collects cash from customers before it has to pay its own suppliers, and that cash helps finance the specialty and nutrition build-out.
3. Nutrition & Health Solutions: from animal-feed vitamins to human wellness
The company is one of the world’s top two producers of Vitamin B3, made from its own in-house raw material at the lowest cost, and it is now pushing that vitamin into regulated human-nutrition and cosmetic markets where approvals take years and margins are higher.
- Fully backward-integrated in B3 - it sources a significant portion of its beta-picoline, the key raw material for niacinamide, from its own pyridine plants using a green route, and a niche air-oxidation process gives it the lowest production cost globally.
- The human-nutrition pivot - a new cGMP-compliant facility at Bharuch, commissioned in early 2025, makes food- and cosmetic-grade niacinamide for dietary supplements, energy drinks, and infant nutrition, and the company has already entered the human-grade choline market for liver and brain health.
- Approval barriers protect the business - getting a new nutrition ingredient approved by customers takes roughly three to five years of product testing and facility audits, so once the company is qualified, competitors cannot easily displace it.
- Acquisition adds the premix layer - the purchase of Remidex Pharma in March 2026 brings in-house capability to make micronutrient premixes and nutraceuticals, moving the business up the value chain from selling single vitamins to selling finished formulations.
- Animal feed still pays the bills - it supplies over 24 branded feed additives to more than 450 customers in poultry, dairy, aqua and pet food, and holds domestic market leadership in Vitamin B4 (choline chloride).
Group structure and partners
The company sits inside the Jubilant Bhartia Group, a USD 6 billion Indian conglomerate, and uses a network of subsidiaries and joint ventures to run manufacturing, global distribution, and renewable-energy supply.
- A clean demerger created it - the company was formed in February 2021 by separating the life-science ingredients business from Jubilant Pharmova, and five subsidiaries came with it on day one.
- Agro subsidiary landed the mega-order - wholly-owned Jubilant Agro Sciences Limited operates the dedicated facility that will fulfil the agrochemical CDMO contract, with commercial production and first dispatch starting in March 2026.
- Global sales arms - wholly-owned subsidiaries in the US, Singapore, and China handle sales, distribution and business transactions in their respective regions.
- A bet on plant-based meat - it owns a 37.98% stake in Mister Veg Foods, an Indian maker of plant-based meat analogues, creating a potential downstream outlet for its nutrition ingredients.